Navigation Links
Pfenex Inc. Establishes Reagent Protein Distribution Agreement With Cedarlane Corporation
Date:8/24/2010

SAN DIEGO, Aug. 24 /PRNewswire/ -- Pfenex Inc. and Cedarlane today announced that they have entered into a non-exclusive distribution agreement. Cedarlane will market and distribute high value reagent proteins produced by Pfenex to researchers in Canada and the United States. Among the products initially distributed will be vaccine carrier proteins such as CRM197 and Cholera Toxin B and cell culture related growth factors including G-CSF and Interferon beta 1-b. New products which are developed by Pfenex will be added to the Cedarlane catalogue upon launch.

"We are pleased to establish this distribution relationship with Cedarlane," stated Patrick K. Lucy, Vice President, Business Development at Pfenex Inc. "Leveraging the Pfenex Expression Technology™ platform, we are now producing and making available complex reagent proteins to meet the needs of the biotech R&D and clinical development community. As Pfenex grows its reagent proteins business, we welcome the opportunity to work with world class distributors such as Cedarlane to enable placing Pfenex products in the hands of life science researchers around the world."

"CEDARLANE is proud to add Pfenex Inc. products to its extensive portfolio," said John Course, CEDARLANE Vice President. "Canadian scientists have an even greater opportunity to consolidate their ordering from a long list of high-quality suppliers of scientific reagents." Key components of the CEDARLANE mission are to provide quality products, assure the highest in customer satisfaction and respond to the dynamic needs of every research community.

About Pfenex Inc.

Pfenex Inc. is a protein production company leveraging the unique and powerful Pfenex Expression Technology™ platform based on the microorganism, Pseudomonas fluorescens, for the production of research proteins, reagent proteins, biosimilars and innovator biopharmaceuticals. For more information please visit www.pfenex.com

About CEDARLANE

In business since 1957 and incorporated in 1975, CEDARLANE is a 100% Canadian Corporation and a leading supplier of research reagents in North America and worldwide. The company is ISO 9001 accredited and ISO 13485 certified.

www.pfenex.com

www.cedarlanelabs.com


'/>"/>
SOURCE Pfenex Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pfenex Inc. Awarded Contract With the United States Federal Government Potentially Totaling Up to $18.8 Million to Develop a Robust Pfenex Expression Technology Based Process for the Production of Bulk Recombinant Protective Antigen (rPA) From Anthr
2. Pfenex Grants Exclusive License to Merck & Co., Inc. for the Production of Proteins for Undisclosed Vaccine Program
3. Mach 7 Technologies Establishes New Headquarters in Burlington, VT
4. Renhuang Appoints New Director and Establishes Nominating and Compensation Committee
5. BD Establishes $1.2 Million Fund for Haiti Earthquake Relief Efforts
6. FUJIFILM Establishes Medical Informatics Organization
7. First Candidate from Esperances Targeted Anti-cancer Platform, EP-100, Establishes Preclinical Proof of Concept
8. Pharmaxis Establishes Named Patient Program for Bronchitol
9. Transgenomic Establishes Collaboration With the National Cancer Institute to Investigate Mitochondrial Genome and Associated Nuclear Genes in Cancer Cell Lines
10. Medicare Contractor Establishes Reimbursement Coding Guidance for Monograms Trofile Assay
11. New England Biolabs Launches NEBNext™ Quick DNA Sample Prep Reagent Sets for Use With Roche/454 Next Generation Sequencing Platforms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/5/2017)... MINNEAPOLIS , July 5, 2017 Pace Analytical, a company of ... announcing today that they have acquired ESC Lab Sciences, further solidifying their position ... the United States . ... Steve Vanderboom- President and CEO of Pace Analytical ... of ESC Lab Sciences out of Mt Juliet, TN , ...
(Date:6/30/2017)... Md. , June 30, 2017 In ... since the start of May, at least ten diagnostic ... include private investments, public offerings and a loan facility.  ... million to almost $80 million.  Kalorama Information provides a ... of its Diagnostics Knowledge Center. ...
(Date:6/27/2017)... TEL AVIV, Israel , June 27, 2017 /PRNewswire/ ... a specialty clinical-stage pharmaceutical company specializing in the development ... ring The Nasdaq Stock Market Opening Bell in ... 28, 2017 in honor of its initial public offering ... Nasdaq Capital Market in March 2017. Dr. ...
Breaking Medicine Technology:
(Date:7/24/2017)... ... July 24, 2017 , ... ... announced that they have enrolled over 100,000 children in their treatment program. Clubfoot ... every year in areas where treatment is limited or non-existent. Without intervention, these ...
(Date:7/24/2017)... Church, VA (PRWEB) , ... July 24, 2017 ... ... figuring out how to change manufacturers future. , The agency is hammering out ... Cures Act, one of the farthest-ranging laws ever to affect FDA-regulated firms. The ...
(Date:7/24/2017)... ... July 24, 2017 , ... “The Perfect Gift”: a customizable and interactive Bible study guide ... Huckett is a born-again Christian. She has always accepted Christ as her Savior, yet ... She was in the Spirit when she wrote this book to her children, so they ...
(Date:7/24/2017)... ... ... “Journey to the Light: The Quest for Happiness and Love. . . through ... herself. “Journey to the Light: The Quest for Happiness and Love. . . ... newsletters, manuals, and articles, who has recently decided to expand her literary horizons and ...
(Date:7/23/2017)... ... July 23, 2017 , ... ... education and training standards for healthcare treatment providers, offers healthcare professionals a ... iaedp™ Core Curriculum. , Presented as either online or as a 2-day, ...
Breaking Medicine News(10 mins):